BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Jeff Collins was elected to a 3-year term on the Board of Directors of NCBIO at its annual meeting, in Winston-Salem, NC
News | 05. 19. 2008
NCBIO elected four new members to the organization’s Board of Directors and re-elected six other individuals at the annual meeting in Winston-Salem, May 19th. Jeff Collins, Executive in Residence, Pappas Ventures; Norris Tolson, President and CEO of the NC Biotechnology Center; Susan Thomason, Executive Director Global Business Development, NovaQuest; and Jan Turek, President and CEO of Biolex Therapeutics will serve until 2011.
